| Name | Title | Contact Details |
|---|
You will find comfort, security, and gracious services that exceed your expectations in our communities. A caring staff will provide thoughtful attention to your needs. Old friends will want to visit. New neighbors will welcome you. The amenities of shops, restaurants, entertainment, events and churches are readily accessible in town. Year after year, residents and staff award our communities the highest satisfaction ratings in an independent survey.
Advantage Medical Equipment is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anesthesia Service Inc is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PaxeraHealth (Formerly Paxeramed) is a leading healthcare solution developer based in Boston, MA. We develop a full range of medical imaging solutions including PACS, RIS, VNA, multi-modality workstations, mobile App viewers, patient portal, dental PACS, Vet PACS, advanced visualization, Patient engagement and enterprise solutions. Leveraging technology and staying at the forefront of new healthcare IT technological developments is a high priority for PaxeraHealth. The company develops the next generation medical imaging and Patient engagement technologies designed to automate clients` workflow, elevate patient care and cut healthcare costs.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.